Lɛ wi lan bɔt nyu mɛrɛsin dɛn we de ɛp fɔ mek pɔsin gɛt dayabitis ɛn fɔ lɛf fɔ gɛt bɔku bɔku bɔdi? (GLP-1 Agɔnis dɛn) .

Yu go mɔs dɔn yɛri bɔt wan nyu kayn injɛkshɔn we kin ɛp fɔ mek pɔsin gɛt dayabitis ɛn fɔ lɛf fɔ it bɔku bɔku it. Sɔntɛm yu dɔn yɛri yu padi ɔ fambul tɔk bɔt am. So, dis nyu klas fכ drog we bכku pipul dεn de tכk bכt dεn kכl am GLP-1 agonist. Lɛ wi ɛksplen ɔltin bɔt am tide, lɛk se wi de tɔk to wi padi.

Wetin na dɛn GLP-1 Agonist ya?

Fɔ tɔk am simpul wan, GLP-1 agonist na wan klas ɔf mɛrɛsin we de ɛp fɔ kɔntrol di blɔd shuga lɛvɛl na pipul dɛn we gɛt tayp 2 dayabitis. Nɔto dat nɔmɔ, dɛn kin yuz sɔm pan dɛn mɛrɛsin ya bak fɔ mɛn pipul dɛn we fat.

Bɔrku tɛm, dis mɛrɛsin kin kam lɛk injɛkshɔn. Dat min se yu kin gi am to yusɛf yuz sirinj ɛn nidul. dis injεkshכn fכ gi insay di fεt layεr כnda di skin. spεshal wan, yu kin gi dis injεkshכn na di bכdi, di bak pat na di tכŋ, di כp pat pan di bכtכm, εn di bak pat pan di an.

Dɛn kin kɔl dis klas fɔ drɔgs wit sɔm ɔda nem dɛn. Yu nɔ nid fɔ no dɛn ɔl, bɔt if yu si dɛn, yu fɔ ɔndastand se dɛn ɔl de tɔk bɔt di sem tin.

• Pεptida-1 agonist dεm we lεk glukagכn
• GLP-1 rεsεptכr agonist dεm
• Incretin mimɛtik dɛn
• GLP-1 analɔg dɛn

Dis kayn mɛrɛsin na nyu tin. Di fɔs GLP-1 agonist (Exenatide) bin apruv insay 2005. So risach pipul dɛn stil de fɛn di ɔda yus ɛn bɛnifit dɛn fɔ dis mɛrɛsin.

Wetin na di kayn GLP-1 agonist mεdikeshכn dεm we de naw?

Dis na sɔm pan di men GLP-1 agonist mɛrɛsin dɛm we de na di makit naw. Sɔntɛm yu dɔktɔ dɔn tɛl yu wan pan dɛn tin ya.

Apat frɔm dis, ɔda klas de fɔ drɔgs we de wok di sem we. dεn kכl dεm dual GLP-1/GIP rεsεptכr agonist dεm. Naw, wan mɛrɛsin de we tan lɛk dis. Dat na Tirzepatide (Mounjaro®).

Aw dis mɛrɛsin de wok insay di bɔdi?

Fɔ ɔndastand aw dis mɛrɛsin de wok, wi fɔs nid fɔ no smɔl bɔt wan ɔmon we dɛn kɔl GLP-1 we de na wi bɔdi na wi bɔdi.

GLP-1 na wan ɔmon we yu smɔl intestinal de mek. I tan lɛk mɛsenja insay wi bɔdi. I de du sɔm impɔtant tin dɛn:

1. I de mek di pankrias mek insulin: Insulin na impɔtant ɔmon we de ɛp fɔ chenj di it we wi de it to ɛnaji. I de du dis bay we i de ridyus di shuga (glukɔs) we de na di blɔd. If insulin nɔ de, di blɔd shuga go go ɔp ɛn dayabitis kin kam. so di GLP-1 כmon de gi di pankrias wan "signal", we de se, "Okay, prodyuz insulin naw."

2. I de stɔp di ɔmon we dɛn kɔl Glucagon: Glucagon na ɔmon we de wok agens insulin. Dat min se, i de *inkris* di blɔd shuga lɛvɛl we nid de. So, we di ɔmon GLP-1 de stɔp fɔ mek glukagon, i de mek dɛn nɔ ad ɛkstra shuga to di blɔd.

3. I de slo di ɛmti we di bɛlɛ de ɛmti: Fɔ tɔk am simpul wan, i de mek di tɛm we di it we yu de it de na yu bɛlɛ, bɔku. Dis kin mek di shuga we de kɔmɔt na di it go insay yu blɔd sloslo. Dis kin ɛp fɔ kɔntrol di shuga we de na di blɔd we kin go ɔp wantɛm wantɛm.

4. 4. .I de mek di filin fɔ ful-ɔp afta yu it: Di GLP-1 ɔmon de afɛkt bak di pat dɛn na wi bren we de kɔntrol angri ɛn ful-ɔp. So, wi kin fil ful ivin afta wi dɔn it smɔl, ɛn wi nɔ kin want fɔ it igen.

Naw, yu ɔndastand aw di natura GLP-1 ɔmon de wok? Okay, naw mek wi si wetin de apin wit di drɔg. wetin wan GLP-1 agonist dכg de du na fכ bihayv lεk di nεchכral כmon. Dat min se, i de "mimic" da ɔmon de. we di dכg go insay di bכdi, i de tay pan di rεsεpכta dεm fכ di GLP-1 כmon εn i de du di sem tin we wi bin dכn tכk bכt. As di doz fɔ di drɔg de go ɔp, dis ifɛkt de go ɔp bak.

If yu gɛt tayp 2 dayabitis, dis mɛrɛsin de kɔntrol di blɔd shuga bay we i de mek insulin bɔku ɛn kɔntrol di we aw yu bɛlɛ de ɛmti.

Bikɔs i kin mek pɔsin fil lɛk se i ful-ɔp, di it we pɔsin kin it kin go dɔŋ, ɛn i nɔ kin want fɔ it igen. We dɛn put ɔl dɛn tin ya togɛda, di tin we kin apin kin mek i nɔ gɛt bɔku bɔku bɔdi.

Udat fɔ yuz dis mɛrɛsin?

Dɔktɔ dɛn kin gi dis mɛrɛsin mɔ fɔ tu tin dɛn: tayp 2 dayabitis ɛn fɔ fat.

Tayp 2 Dayabitis

Dɛn dɔn gri fɔ gi GLP-1 agonist fɔ trit dayabitis bikɔs dɛn kin rili wok fɔ mek di blɔd shuga lɛvɛl go dɔŋ.

Ɔda mɛrɛsin dɛn de fɔ mek pɔsin gɛt dayabitis. Metformin na di fɔs tin we dɛn kin pik. Bɔt yu dɔktɔ kin tɛl yu fɔ yuz GLP-1 agonist pan dɛn kayn tin ya:

• If dɛn nɔ kɔntrol dayabitis fayn wit mɛtfɔmin nɔmɔ.
• If yu gɛt wɛl bɔdi prɔblɛm wae de mek yu nɔr de tek mɛtfɔmin.
• If yu A1C valyu bɔku pas di target lɛvɛl.
• If dɛn nɔr kɔntrol yu A1C afta tri mɔnt we yu dɔn trit yu ɛn yu gɛt ɔda mɛrɛsin lɛk atherosclerosis , at failure , ɔ krεse kidni sik.

Fat

Sɔm GLP-1 agonist dɛm, lɛk Semaglutide ɛn ay-dos Liraglutide, dɛn dɔn gri fɔ trit pɔsin we fat pasmak, bikɔs dɛn gɛt di potenshal fɔ ridyus di bɔdi wet bad bad wan. Fat na wan sik we nɔ de mɛn we yu bɔdi mas indeks (BMI) de 30 ɔ pas dat.

Dɔn bak, dɔktɔ kin gi dis mɛrɛsin to pɔsin we gɛt BMI bitwin 25 ɛn 29.9 (we gɛt bɔku bɔku bɔdi) ɛn we gɛt ɔda sik dɛn we pɔsin kin kɔntrol bay we i lɛf in wet.

Aw ɛn aw ɔltɛm fɔ yuz di mɛrɛsin

Yu dɔktɔ go tɛl yu klia wan ustɛm ɛn aw ɔltɛm fɔ tek dis mɛrɛsin. I rili impɔtant fɔ fala dɛn instrɔkshɔn dɛn de di rayt we. Di nɔmba we dɛn kin yuz fɔ yuz dis injɛkshɔn de sho na di tebul we de dɔŋ ya.

Semaglutide de kam bak insay tablɛt fɔm. Na mɛrɛsin we pɔsin fɔ tek ɛvride.

Wetin na di ɔda bɛnifit dɛn we dis mɛrɛsin de gi?

Apat frɔm we dɛn de mek di blɔd shuga go dɔŋ ɛn lɛf fɔ gɛt bɔku bɔku bɔdi, risach dɔn sho se dɛn mɛrɛsin ya gɛt bɔku ɔda bɛnifit dɛn.

• Fɔ mek di blɔd prɛshɔn go dɔŋ.
• Fɔ mek di lipid disɔda lɛk di kɔlɔstrel we de na di blɔd bɛtɛ.
• Fɔ ridyus di sik we de na di liva we gɛt fat.
• Fɔ ridyus di risk fɔ gɛt at sik ɛn kidni sik.
• Kɔntrol di rit fɔ dayabitik nɛfrɔpati (kidni damej we dayabitis kin mek).

Lɛ wi lan bak bɔt di bad tin dɛn we kin apin to wi.

Lɛk ɛni mɛrɛsin, GLP-1 agonist kin mek sayd ɛfɛkt. Bɔt, bɔrku pipul nɔr kin gɛt dɛn kayn tin ya, ɛn if dɛn kin gɛt dis sik, dɛn kin go afta sɔm dez.

Risk ɛn Kɔmplikɛshɔn dɛn

GLP-1 agonist dεm na jεnarali sef mεdikeshכn, bכt sכm risk dεm de fכ no.

Riakshɔn dɛn we pɔsin kin gɛt we i gɛt alɛji

Sɔm pipul dɛn kin gɛt alɛji fɔ dis mɛrɛsin. If yu de it ɔ rɛd ɔltɛm na di say we dɛn inj yu, tɔk to yu dɔktɔ. Na smɔl tɛm nɔmɔ, siriɔs alɛji we dɛn kɔl anafylaksis kin apin. If yu gɛt ɛni wan pan dɛn sik ya, kɔl ambulans ɔ go na di imejensi rum (ETU) we de nia yu.

• I nɔ kin izi fɔ yu fɔ blo
• Hiv dɛn
• I nɔ izi fɔ swɛla
• Wan rɛd rɛd rash
• Bɛlɛ de pen
• Chɛst tayt

Yuz am we yu gɛt bɛlɛ

GLP-1 agonist dεm nכ de rεkomεnd fכ yuz we uman bεlε. Stɔdi dɛn we dɛn dɔn du pan animal dɛn dɔn sho se dis mɛrɛsin kin ambɔg di pikin we de divɛlɔp. Yu fɔ yuz di rayt bɔn kɔntrol fɔ mek yu nɔ gɛt bɛlɛ we yu de tek dis mɛrɛsin. If yu gɛt bɛlɛ we yu de tek dis mɛrɛsin, go to yu dɔktɔ wantɛm wantɛm.

Di blɔd shuga lɛvɛl smɔl (Hypoglycemia) .

Di risk fɔ lɛ yu blɔd shuga nɔ bɔku (haypoglycemia) nɔ bɔku we yu tek dis mɛrɛsin nɔmɔ. Bɔt if yu tek ɔda mɛrɛsin fɔ dayabitis, lɛk insulin ɔ sulfonylureas, wit dis mɛrɛsin, dis risk kin bɔku.

haypoglycemia na wan kכndyushכn we di bכdi shuga lεvεl de dכn dכn 70 mg/dL. If dɛn nɔ trit am kwik, i kin mek pɔsin in layf de pan denja.

Karakta:

• Di bɔdi we de shek shek
• Swet ɛn fil kol
• Diziz ɛn blu yay
• Bɔdi we nɔ gɛt layf
• Di at we de blo
• Fɔ fil se i rili angri
• I nɔ kin izi fɔ mek yu pe atɛnshɔn to yu
• Pale skin
• Vɔmit

If yu gɛt dɛn sik ya, yu fɔ it sɔntin we gɛt shuga ɔ kabɔhaydrɛt kwik kwik wan. Fɔ ɛgzampul, yu kin it af banana ɔ af kɔp apul jus.

Ustɛm a fɔ tɔk to di dɔktɔ?

If yu de yuz GLP-1 agonist, yu fɔ go to yu dɔktɔ ɔltɛm fɔ si aw i de wok fayn. Apat frɔm dat, tɔk to yu dɔktɔ bɔt dɛn tin ya:

• If di sayd ɛfɛkt dɛn de mɔna yu.
• If yu fil se de mɛrɛsin nɔr de ɛp yu sik.
• If yu fil fɔ stɔp di mɛrɛsin.
• If yu gɛt bɛlɛ ɔ yu de plan fɔ gɛt bɛlɛ.